Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

Míreanna comhchosúla

• Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
  de réir: Taylor, P, et al.
  Foilsithe / Cruthaithe: (2011)
• The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
  de réir: Natalia Vladimirovna Chichasova
  Foilsithe / Cruthaithe: (2014-12-01)
• Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings
  de réir: Fumiko Yamairi, et al.
  Foilsithe / Cruthaithe: (2020-08-01)
• Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
  de réir: Aaron Broadwell, et al.
  Foilsithe / Cruthaithe: (2023-03-01)
• THE EFFECT OF GOLIMUMAB ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
  de réir: L. A. Knyazeva, et al.
  Foilsithe / Cruthaithe: (2018-03-01)